Cargando…
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study
Next-generation sequencing (NGS) is used to investigate the presence of somatic mutations. The utility of incorporating routine sequencing to guide diagnosis and therapeutic decisions remains unclear. We report the findings of an observational, multicenter study that aimed to assess the impact of so...
Autores principales: | Vantyghem, Sophie, Peterlin, Pierre, Thépot, Sylvain, Ménard, Audrey, Dubruille, Viviane, Debord, Camille, Guillaume, Thierry, Garnier, Alice, Le Bourgeois, Amandine, Wuilleme, Soraya, Godon, Catherine, Theisen, Olivier, Eveillard, Marion, Delaunay, Jacques, Maisonneuve, Hervé, Morineau, Nadine, Villemagne, Bruno, Vigouroux, Stéphane, Subiger, François, Lestang, Elsa, Loirat, Marion, Parcelier, Anne, Godmer, Pascal, Mercier, Mélanie, Trebouet, Adrien, Paz, Damien Luque, Le Calloch, Ronan, Le Clech, Lenaig, Bossard, Céline, Moreau, Anne, Ugo, Valérie, Hunault, Mathilde, Moreau, Philippe, Le Gouill, Steven, Chevallier, Patrice, Béné, Marie C., Le Bris, Yannick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927891/ https://www.ncbi.nlm.nih.gov/pubmed/32241844 http://dx.doi.org/10.3324/haematol.2019.242677 |
Ejemplares similares
-
A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia
por: Peterlin, Pierre, et al.
Publicado: (2020) -
Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft
por: Jullien, Maxime, et al.
Publicado: (2020) -
Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies
por: Chevallier, Patrice, et al.
Publicado: (2018) -
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
por: Le Calvez, Baptiste, et al.
Publicado: (2020) -
Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease
por: Lodé, L, et al.
Publicado: (2013)